Home › Funds › EcoR1 Capital, LLC › LKFT
EcoR1 Capital, LLC position in LKFT
LAKEFRONT BIOTHERAPEUTICS NV
EcoR1 Capital, LLC reported holding 1,667,119 shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV) in its Q2 2026 13F filing — a position valued at US$50.0M, representing 2.57% of its reported portfolio and ranking #8 among its reported holdings. EcoR1 Capital, LLC has disclosed LKFT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How EcoR1 Capital, LLC's LKFT position evolved
EcoR1 Capital, LLC first disclosed a stake in LKFT in Q3 2023 at 5,756,268 shares (US$198.9M). The position peaked in Q4 2023 at 5,756,268 shares, worth US$234.0M. Across 12 filings, EcoR1 Capital, LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 1,667,119 shares valued at US$50.0M. Notable position changes include a 97% trim in Q3 2024 (shares fell 4% over the following quarter), a 569% increase in Q2 2025 (shares rose 24% over the following quarter), a 61% increase in Q3 2025 (shares fell 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.76M | $198.88M | New |
| Q4 2023 | 5.76M | $233.99M | Hold |
| Q1 2024 | 5.76M | $185.35M | Hold |
| Q2 2024 | 5.76M | $142.64M | Hold |
| Q3 2024 | 155.01K | $4.46M | Reduce |
| Q4 2024 | 155.01K | $4.26M | Hold |
| Q1 2025 | 155.01K | $3.89M | Hold |
| Q2 2025 | 1.04M | $29.02M | Add |
| Q3 2025 | 1.67M | $57.75M | Add |
| Q4 2025 | 1.67M | $54.51M | Hold |
| Q1 2026 | 1.67M | $50.01M | Hold |
| Q2 2026 | 1.67M | $49.98M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LKFT and 13F data
LKFT (LAKEFRONT BIOTHERAPEUTICS NV) is a company whose sector is not yet classified in our data. 17 other funds we track also report a position in LKFT — the largest reported positions include GILEAD SCIENCES, INC. (US$500.2M), TANG CAPITAL MANAGEMENT LLC (US$113.5M), Madison Avenue Partners, LP (US$103.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LKFT
- GILEAD SCIENCES, INC. 16.71M sh · $500.16M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 3.79M sh · $113.50M · Q2 2026
- Madison Avenue Partners, LP 3.45M sh · $103.37M · Q2 2026
- Prosight Management, LP 2.04M sh · $61.26M · Q2 2026
- DME Capital Management, LP 482.75K sh · $14.47M · Q2 2026
- DAFNA Capital Management LLC 130.18K sh · $3.90M · Q2 2026
More on EcoR1 Capital, LLC
FAQ
How long has EcoR1 Capital, LLC held LKFT?
EcoR1 Capital, LLC has disclosed LKFT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is EcoR1 Capital, LLC's current position in LKFT?
As of Q2 2026, EcoR1 Capital, LLC holds 1.67M shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV), valued at $49.98M, representing 2.57% of its reported portfolio and ranking #8.
Has EcoR1 Capital, LLC been buying or selling LKFT?
In the latest 13F filing (Q2 2026), EcoR1 Capital, LLC held unchanged its position in LKFT. The position peaked in Q4 2023 at 5.76M shares.
Which other funds hold LKFT?
Other major institutional holders of LKFT include GILEAD SCIENCES, INC., TANG CAPITAL MANAGEMENT LLC, Madison Avenue Partners, LP, among 17 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.